Mar. 24 at 3:54 PM
$INAB $GILD acquired private biotech company Ouro Medicine, an early-stage TCE biotech company, for
$2.1 billion. The acquisition involves a cost-sharing agreement with
$GLPG. TCE assets have been highly sought after in the biotech deal landscape recently. For instance,
$SNY committed another
$1 billion yesterday for a deal with California-based Kali Therapeutics, another early-stage TCE biotech company.
INAB has a strong chance of securing a deal if INB-619 demonstrates promising data later this year.
